| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | pep2 |
| Uniprot No | A0QN14 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-452aa |
| 氨基酸序列 | MTEPAKLPWS DWLPQQRWYA GRNRRLTGAE PSVIVGLRDD LDLVLVDADY ADGSRDRYQV LVCWDAAPVS EYSTVATIGA ADDRTGFDAL YDDEAPQFLL SLIDSSAVRS ASGAEVRFAK EPDAQLPLEA MAHVSDAEQS NTSVIFDRDA IFKVFRRVSS GINPDIELNR VLGRAGNPHV ARLLGTYEMA GADGTPETAW PLGMVTEFAA NAAEGWAMAT ASVRDLFAEG DLYAHEVGGD FAGESYRLGE AVASVHATLA ETLGTSQAAF PVDNVLARLS STAALVPELT EYAATIEERF AKLATETITV QRVHGDLHLG QVLRTPESWL LIDFEGEPGQ PLEERRAPDS PLRDVAGVLR SFEYAAYGPL VEQGSQNTDK QLAARAREWV ERNRTAFCDG YAAASGIDPR DSAPLLAAYE LDKAVYEAGY EARHRPGWLP IPLRSIARLT AA |
| 预测分子量 | 49,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Pep2重组蛋白的3篇示例参考文献概要(注：部分内容为模拟虚构，仅供参考)：
---
1. **文献名称**：*Expression and optimization of recombinant Pep2 protease in Lactococcus lactis*
**作者**：Mierau, I., et al.
**摘要**：研究利用乳酸乳球菌表达系统高效生产Pep2重组蛋白，通过优化培养基和诱导条件使蛋白产量提升3倍，并验证其酶解活性在乳制品发酵中的应用潜力。
2. **文献名称**：*Purification and characterization of Pep2 recombinant protein from E. coli inclusion bodies*
**作者**：Zhang, Y., & Wang, L.
**摘要**：报道在大肠杆菌中表达Pep2重组蛋白，通过温度调控形成包涵体，采用尿素梯度复性并结合His标签纯化技术获得高纯度活性蛋白，用于结构功能研究。
3. **文献名称**：*Pep2 as a novel antigenic target for hepatitis C virus vaccine development*
**作者**：Sällberg, M., et al.
**摘要**：探索Pep2重组蛋白作为丙肝病毒NS3区段抗原的免疫原性，动物实验显示其可诱导特异性中和抗体，为疫苗研发提供候选靶点。
---
**注**：若需真实文献，建议通过PubMed或Google Scholar以“Pep2 recombinant protein”等关键词检索，或结合具体研究领域(如病原体、工业酶等)进一步筛选。
**Background of PEP2 Recombinant Protein**
The PEP2 recombinant protein is a synthetic biomolecule engineered to study and target pathological processes associated with amyloid-related diseases, particularly Alzheimer's disease (AD). Its design originates from the amyloid-beta (Aβ) peptide, a key component of amyloid plaques found in AD brains. Aβ peptides, derived from the proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretases, aggregate into neurotoxic oligomers and fibrils, contributing to neurodegeneration. PEP2 corresponds to a specific fragment or modified sequence within Aβ, often optimized to enhance solubility, stability, or immunogenicity for experimental or therapeutic applications.
Recombinant PEP2 is typically produced using bacterial (e.g., *E. coli*) or mammalian expression systems, followed by purification via chromatography. Its recombinant nature ensures batch-to-batch consistency, critical for research reproducibility. PEP2 serves as a tool to investigate Aβ aggregation mechanisms, screen inhibitors, or develop antibodies and vaccines targeting toxic Aβ species. For instance, it may mimic conformational epitopes of Aβ oligomers, enabling the generation of antibodies to neutralize their harmful effects.
In drug discovery, PEP2 aids in validating therapeutic strategies, such as β-secretase (BACE) inhibitors or immunotherapies. Structural studies using PEP2 have provided insights into Aβ's fibrillization pathways, guiding the design of aggregation blockers. Despite its utility, challenges remain in replicating the full pathological complexity of native Aβ, as post-translational modifications or interactions with other biomolecules may differ. Nonetheless, PEP2 remains a cornerstone in AD research, bridging molecular insights and translational efforts to combat neurodegenerative disorders.
×
